Has Sam Fereidouni, MD received payments from drug or device companies?

Yes. Drug and device makers reported $486,269 in general payments to Sam Fereidouni, MD across 1,998 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sam Fereidouni, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sam Fereidouni, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sam Fereidouni, MD

Family Medicine · Scottsdale, AZNPI 1003007048

Payments from drug & device makers

$486,269in general payments, 2019–2025

Across 1,998 payments — averaging $243.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$209K
Novo Nordisk$136K
Bayer$35K
Amgen$35K
Abbott$23K
Johnson & Johnson$14K
plus $34K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	457	$209,203
Novo Nordisk	279	$135,751
Bayer	55	$34,814
Amgen(2 entities)	124	$34,739
Abbott	54	$23,488
Johnson & Johnson	27	$13,990
Nestle Healthcare Nutrition Inc.	48	$11,768
Merck	29	$4,131
AbbVie(2 entities)	253	$3,882
AstraZeneca	84	$2,362
Sanofi-aventis U.S. LLC	38	$2,248
Novo Nordisk AS	1	$1,080
Antares Pharma, Inc.	75	$923
Pfizer	50	$710
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	49	$684
Boehringer Ingelheim	40	$657
Takeda Pharmaceuticals U.S.A., Inc.	38	$487
GSK	28	$485
Mannkind Corporation	21	$311
Novartis	14	$266
Arbor Pharmaceuticals, Inc.	22	$260
Medtronic(3 entities)	12	$244
Madrigal Pharmaceuticals	7	$234
Amarin Pharma, Inc.	13	$194
Corcept Therapeutics	10	$177
Biohaven Pharmaceutical Holding Company Ltd.	7	$160
E.r. Squibb & Sons, L.L.C.	8	$150
Aimmune Therapeutics, Inc.	6	$142
Xeris Pharmaceuticals, Inc.	7	$134
Lundbeck LLC	7	$124
Boston Scientific	6	$114
Dexcom, Inc.	5	$113
BETA Bionics, Inc.	7	$103
Paratek Pharmaceuticals, Inc.	6	$91
Otsuka America Pharmaceutical, Inc.	4	$86
Genentech USA, Inc.	5	$85
Astellas Pharma US Inc	4	$78
BD	3	$72
Exact Sciences	3	$71
Halozyme Inc	4	$70
Nalpropion Pharmaceuticals LLC	4	$70
Cequr Corporation	2	$69
Edwards Lifesciences	2	$66
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	4	$63
Insulet Corporation	3	$62
Gilead	4	$58
Esperion Therapeutics, Inc.	3	$54
Eisai Inc.	3	$52
Biohaven Pharmaceuticals, Inc.	3	$50
Organogenesis Inc.	2	$49
Idorsia Pharmaceuticals US Inc	3	$47
Bausch Health US, LLC	3	$46
Clarus Therapeutics Inc.	3	$45
Teva Pharmaceuticals USA, Inc.	1	$43
Currax Pharmaceuticals LLC	2	$39
Dermira, Inc.	2	$39
Organon	2	$38
Lucid Diagnostics Inc.	1	$37
Optinose US, Inc.	2	$36
Avanir Pharmaceuticals, Inc.	2	$33

How this compares

$486,269 in reported general payments places this provider in the 95th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona →

Medicare billing

Part B allowed, 2024

$551,022

Medicare patients

753

Services billed

9,215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family medicine in Scottsdale

Danielle ArmasScottsdale$73M
Joseph LilloScottsdale$6.3M
Casey MyersScottsdale$246K
Terry O'ReillyMesa$35.8M
Shawn SearleChandler$27M
Corey AndersonMesa$21.5M
Dena PetersenTucson$14.7M
Gerald ShockeyMesa$12.3M
Brock MerrittPhoenix$8.4M
John McGettiganTucson$8.3M

See the full list for Arizona →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →